论文部分内容阅读
对绝经后妇女口服或经皮给雌激素(E)能防止骨质丢失,甚至增加椎骨及髋骨骨质,但均系横向而缺少纵向研究的报道。为此作者对连续三年皮埋雌二醇(E_2)的绝经后妇女,进行了总体钙(TBCa),脊椎骨矿密度(BMD)和桡骨骨矿含量(BMC)的三年检测纵向研究。 对象为29名经子宫切除的妇女,年龄37～55岁,前2年已有更年期综合征。皮理E_2的量为100mg、50mg或25mg,间隔约6个月,为期三年。在再次皮埋的前一个月测血E_2值,旨在要维持血浆E_2水平500pmol/L,如血浆E_2值为750～1000pmol/L,给皮埋E_225mg;250～750pmol/L
Oral or transdermal administration of estrogen (E) to postmenopausal women prevents bone loss and even increases the vertebral and hip bone mass, both transverse and lacking longitudinal studies. To this end, the authors conducted a longitudinal study of three years of total calcium (TBCa), spine bone mineral density (BMD), and radial bone mineral content (BMC) in postmenopausal women with three consecutive pregnancies of E2. Subjects for the 29 hysterectomies of women, aged 37 to 55 years old, the first two years have had menopausal syndrome. The amount of epidermal E_2 is 100 mg, 50 mg or 25 mg at intervals of about 6 months for a period of three years. E_2 value measured in the first month after skin burial to maintain plasma E_2 level 500pmol / L, such as plasma E_2 value of 750 ~ 1000pmol / L, to the skin buried E_225mg; 250 ~ 750pmol / L